| abstract |
(57) [Summary] (Corrected) [Structure] General formula (I) [Wherein R 1 : C 2 -C 6 alkenyl group, halogeno C 2 -C 6 alkenyl, (C 6 -C 10 aryl) over C 2 - C 6 alkenyl group, C 2 -C 6 alkynyl group, C 3 -C 7 cycloalkyl group, (C 3 -C 7 cycloalkyl) -C 1 -C 6 alkyl group, (C 5 -C 7 cycloalkenyl) -C 1 -C 6 alkyl group, halogeno-C 1 -C 6 alkyl group ; R 2, R 3: H , C 1 -C 6 alkyl, C 6 -C 10 aryl group; R 4: H, C 1 -C 6 alkyl group; R 5 : C 6 -C 10 aryl group, 5- to 10-membered heteroaryl group; A: C 1 -C 3 alkylene group; X: imino (NH) group, oxygen atom, sulfur atom, CH 2 ; m: 0 − 1; n: 0-1] or a pyrrolopyridazine derivative or a pharmaceutically acceptable salt thereof, and an antiulcer agent containing the compound or a pharmaceutically acceptable salt thereof as an active ingredient. [Effects] This compound has excellent gastric acid secretion inhibitory action and gastric mucosa protective action, as well as Helicobacter pylori It has an excellent antibacterial action against bacterium pylori and is useful as an anti-ulcer agent. |